| Document |
Document Title |
|
WO/2009/041482A1 |
Disclosed is an acetylene compound represented by the general formula (1) below, which is useful as a raw material for fused polymers having high heat resistance. (In the formula (1), the encircled Ar represents an aryl group or a hetero...
|
|
WO/2009/034308A2 |
There is provided a process for preparing sorafenib or a salt thereof comprising the use of a compound of formula (A), wherein R' is selected from the group consisting of hydrogen, -C(O)OA, -C(O)CX3, - OH C(O)NH2, -C(O)-NHOH or (a). Ther...
|
|
WO/2009/035928A1 |
Disclosed are amide, thoiamide, urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and co...
|
|
WO/2009/030752A1 |
The present invention relates to compounds of formula (I) : as well as to cosmetic and pharmaceutical compositions containing such a compound.
|
|
WO/2009/030746A1 |
The present invention relates to compounds of formula (I): and to the cosmetic and pharmaceutical compositions containing such a compound.
|
|
WO/2009/024493A2 |
The invention relates to a novel alkenyl isocyanate characterized by the chemical formula (I). Said compound is obtained by converting isophorone diisocyanate with N-(t-butyl) aminoethyl methacrylate. The novel compound is particularly s...
|
|
WO/2009/025829A1 |
Processes for producing a suitable purity grade of L-Citrulline are disclosed. The processes can include contacting crude L-Citrulline in an aqueous solution with an adsorptive medium at a temperature above approximately 5O0C and below t...
|
|
WO/2009/019199A1 |
The present invention relates to a new crystalline form of R-4- trimethylammonium-3-(tetradecylcarbamoyl)-amino butyrate (also named crystalline Form I of ST 1326 or teglicar), a process for its preparation and pharmaceutical composition...
|
|
WO/2009/015485A1 |
A CPTl inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural ...
|
|
WO/2009/013915A1 |
An inhibitor of plasminogen activator inhibitor-1 (PAI-1). A medicinal composition having an effect of inhibiting the PAI-1 activity and being efficacious in preventing or treating various diseases for the onset of which the PAI-1 activi...
|
|
WO/2009/009278A1 |
Treating pain in mammals with a compound having the formula (I) is disclosed herein.
|
|
WO/2009/001356A2 |
Novel acyl-urea containing compounds, processes of preparing same, compositions containing same and uses thereof in the treatment of neurological diseases and disorders such as epilepsy, neuropathic pain, bipolar disorder, status epilept...
|
|
WO/2008/156816A2 |
The present invention is directed to aspartic protease inhibitors. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to ...
|
|
WO/2008/143070A1 |
Disclosed is a non-covalently-bound polymer which is formed by the self-assembly of an urea compound including a long-chain-alkyl urea. Specifically disclosed is a novel non-covalently-bound polymer which has a simple chemical structure ...
|
|
WO/2008/139121A2 |
The invention relates to a method for the synthesis of (Z)-3-[2-butoxy-3'-(3-heptyl-1 - methyl-ureido)-biphenyl-4-yl]-2-methoxy-acrylic acid having formula (I) and to the method for the synthesis of the reaction intermediates having gene...
|
|
WO/2008/135181A2 |
The present invention relates to the use of 2-aminoindanes for controlling animal pests, especially arthropods, in particular insects. The present invention relates further to specific novel 2-aminoindanes and to compositions of these pe...
|
|
WO/2008/122667A2 |
The invention concerns compounds of Formula (I) or a salt, solvate or pro-drug thereof. The compounds may be used in therapy, particularly anti-cancer therapy.
|
|
WO/2008/113992A2 |
The invention relates to gel composition comprising a gelating agent and a solvent. The gelating agent is a compound of general formula (I): wherein: R1is hydrogen or C1-14 alkyl; R3is OH or a group; R4 is hydrogen or C1-6 alkyl, optiona...
|
|
WO/2008/116145A2 |
Disclosed are urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The co...
|
|
WO/2008/109991A1 |
A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural F...
|
|
WO/2008/107661A1 |
There is provided compounds of formula (I), wherein Rx, Ry, X1, X2, L1, L2, Y1 and Y2 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which...
|
|
WO/2008/107475A1 |
The present invention relates to dialdimines of formula (I) and emulsions and uses thereof. In particular, paste-like hardener and/or accelerator components for polymers having isocyanate groups can be produced therefrom, which component...
|
|
WO/2008/104756A1 |
A compound of formula (I) wherein R1 is C1-6 alkyl optionally substituted by OH, C1-4 alkyl, SH, C1-4 alkylthio, phenyl or indol-3-yl, wherein C1-4 alkyl and C1-4 alkylthio are optionally substituted by phenyl and indol-3-yl is optionall...
|
|
WO/2008/099221A1 |
Compounds of formula (I): or pharmaceutically acceptable salts and esters thereof, are useful for the treatment of obesity, type II diabetes and the metabolic syndrome.
|
|
WO/2008/086047A1 |
Substituted amide and urea derivatives useful as inhibitors of Rho kinase are described, which inhibitors can be useful in the treatment of various disorders such as cardiovascular diseases, cancer, neurological diseases, renal diseases,...
|
|
WO/2008/082735A1 |
Storage-stable organosilane quaternary compounds are provided in the form of adducts with urea (clathrates). The urea-organosilane quaternary clathrates enable the shipment, storage and preparation of compositions without hazardous solve...
|
|
WO/2008/083054A2 |
Novel β1 adrenoreceptor ligands that find use as imaging agents within nuclear medicine applications (e.g., PET imaging and SPECT imaging) are provided. Methods of imaging, including methods of imaging congestive heart failure, are also...
|
|
WO/2008/079683A2 |
The present application is directed to compounds that are TRPV1 antagonists and have formula: (I); wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders ...
|
|
WO/2008/079972A2 |
The compound 4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-
5-yl}carbamoyl)amino]-3-chlorohenoxy}-N-methylpyridine-2-car
boxamide and alternativs forms thereof (e.g., salts, hydrates, solvates, prodrugs, polymorphs and meta...
|
|
WO/2008/078762A1 |
Disclosed are: a study on the synthesis of a novel N-(2-aminophenyl)benzamide derivative having an urea structure and represented by the general formula (1); and the utilization of the pharmacological activity of the derivative. A compou...
|
|
WO/2008/074132A1 |
The invention relates to the inhibition of histone deacetylase. The invention provides compounds, prodrugs thereof, and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods f...
|
|
WO/2008/075150A1 |
The invention relates to compounds of formula (I) in which R is selected from halogen, alkyl, alkoxy, aryl and heteroaryl; R1 is selected from 2-hydroxyethyl, 2,3-dihydroxypropyl, 3-hydroxypropyl, 2,2-dihydroxyethyl, 3,3-dihydroxypropyl,...
|
|
WO/2008/070496A2 |
This present invention provides for cholesteryl ester transfer protein (CETP) inhibitors, of formula Ia and Ib / pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels...
|
|
WO/2008/062859A1 |
A process for the production of phenylalanine derivatives having quinazolinedione rings as represented by the general formula (1) or pharmaceutically acceptable salts thereof:(1) which comprises the following steps (a), (b) and (c): the ...
|
|
WO/2008/059299A1 |
The invention relates to chiral cyclic β-amino acids of Formula (I) and their salts formed with pharmaceutically acceptable acids or bases, wherein the main meanings of the substituents are as follows: R stands for C1-4 Alk; X stands fo...
|
|
WO/2008/040947A2 |
The present invention relates to compounds useful in the preparation of diazoalkanes in general (such as diazomethane, diazoethane, diazopropane, diazobutane and homologues) and to diazomethane (CH2=N=N) in particular. The compounds chos...
|
|
WO/2008/031755A1 |
The invention relates to processes for preparing isocyanates by splitting urethane, said process comprising the following process steps: (i) provision of synthesis gas from natural gas, coal, heavy oil or biomass gasification and product...
|
|
WO/2008/022938A1 |
The present invention relates to compounds of the general Formula (I) wherein (A) is a 5 or 6-membered aromatic or heteroaromatic ring; R1 is cycloalkyl or is aryl or heteroaryl, wherein at least one ring is aromatic in nature, unsubstit...
|
|
WO/2008/015081A1 |
The invention provides a new class of compounds capable of inhibiting carnitine palmitoyl transferase (CPT) having formula (I). The invention also relates to pharmaceutical compositions, which comprise at least one new compound according...
|
|
WO/2008/006625A2 |
Compounds of formula (I): Z is >CH-, >C=CH- or >N-, R1 and R2 are optionally substituted and are the same or different, and each represents an aryl group, a heteroaryl group, or Z, R1 and R2 form a fused ring structure of formula: in whi...
|
|
WO/2008/006812A1 |
The present invention relates to a method for obtaining symmetrical N,N'-disubstituted urea, comprising the step of reacting a reaction mixture comprising a primary amine and phosgene corresponding to the substituents of the urea in an a...
|
|
WO/2008/000969A1 |
The invention relates to compounds of formula (I) wherein R1 is an R4 or NHR4 grouping wherein R4 has the designation defined in the description; R2 is a straight or branched substituted alkyl grouping (C1-C6); and R3 is a hydrogen or ha...
|
|
WO/2007/141423A1 |
The invention concerns phenoxy-isobutyric acid derivatives of general formula (I) wherein: R1 and R2 are H, an alkyl group, or a -OR group where R is an alkyl, or R1 and R2 together form a hydrocarbon ring of 3 to 6 carbon atoms; R3 is H...
|
|
WO/2007/137107A2 |
The present invention relates to compounds of formula (I) wherein R1, R3, X, Q, Z, A, D, m, and n are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.
|
|
WO/2007/134971A1 |
The invention relates to benzoyl-substituted alanines of formula (I), in which the variables R1 to R13 are defined as cited in the description, and to their agriculturally useful salts. The invention also relates to methods and intermedi...
|
|
WO/2007/137103A2 |
The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, m, n, p and q are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.
|
|
WO/2007/137029A1 |
Compounds of the formula (I) or a pharmaceutically acceptable salt thereof or a tautomer thereof, wherein A and B are as described herein, are useful for treating conditions afflicting mammals.
|
|
WO/2007/133531A2 |
A composition comprising a self-emulsifiable or self-dispersible aqueous solution or dispersion of at least one urea linkage-containing alkoxypolyoxyalkylene fluorocarbamate prepared by contacting (a) at least one polyisocyanate which co...
|
|
WO/2007/131336A1 |
This invention relates to iodonium salts, acetal copolymers and polymer binders comprising functional groups capable of undergoing cationic or radical polymerization, their method of preparation and their use in the preparation of coatin...
|
|
WO/2007/130898A1 |
The present invention relates to tetra-substituted urea compounds which are modulators of 11-β hydroxyl steroid dehydrogenase type 1 (11β HSD1), their pharmaceutical compositions, and methods of using the same.
|
